• Agreement calls for Cybin, Catalent to work together to develop novel therapy for treatment-resistant psychiatric disorders
• Cybin looking to identify fast-acting, shorter-duration formulations of CYB003
• Delivering CYB003 through Catalent ODT could provide significant benefits

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has inked a drug-development agreement with Catalent Inc. (NYSE: CTLT), a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products (https://ibn.fm/nQdpg). The agreement, which is scheduled to start this month, calls for the two companies to work together to potentially develop a novel, fast-acting therapy for treatment-resistant psychiatric disorders.

“We are excited to partner with the team at Catalent with the aim of developing fast-acting, shorter-duration formulations of CYB003, recently acquired as part of our acquisition of Adelia Therapeutics,” said Cybin CEO Doug Drysdale. “Our focus on reducing the need for health system resources, such as in-clinic therapist time, is an important part of our goal to create scalable, more accessible treatments for mental health disorders.”

As part of the agreement, Cybin plans on applying Catalent’s proprietary Zydis(R) orally disintegrating tablet (“ODT”) technology to the delivery of CYB003, Cybin’s novel deuterated tryptamine, as a potential therapy for treatment-resistant psychiatric disorders. One of the world’s best-performing ODTs, the proprietary Zydis technology creates a freeze-dried tablet that disperses its contents almost instantly in the mouth without needing water. 

Delivering CYB003 in such a way provides significant potential benefits, including allowing for pre-gastric delivery and preventing first-pass metabolism, which could potentially improve the pharmacokinetic profile of the drug. The partnership will include feasibility studies that include manufacturing and analytical testing of ODT doses containing varying quantities of CYB003 alongside different excipients.

“We look forward to working with Cybin to potentially develop a novel and fast-acting therapy for treatment-resistant psychiatric disorders,” said Catalent president of oral and specialty delivery Jonathan Arnold. “The Zydis platform is an ideal technology to leverage for this type of drug formulation, as pre-gastric absorption is crucial for efficacy.”

Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches, and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.